Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why PharMerica Shares Soared

By Sean Williams - Jan 10, 2014 at 12:00AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

PharMerica issues its preliminary 2014 guidance and investors cheer. Is there still room for shares to move higher or should investors head for the exits?

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of PharMerica ( PMC ), a pharmacy services company that delivers prescription and nonprescription medication to health care facilities, hospitals, and patients outside of hospitals, jumped as much as 24% after the company issued preliminary 2014 guidance and announced the acquisition of privately held BGS Pharmacy Partners.

So what: PharMerica said it anticipates earning from $1.35-$1.50 per share in adjusted earnings per share in 2014 on revenue of $1.67 billion-$1.72 billion. By comparison, Wall Street estimates had called for $1.47 in EPS on just $1.52 billion in revenue. PharMerica outlined its two-pronged approach  in its guidance which encompasses a restructuring effort designed to realize $50 million in annual cost savings, which should be implemented by the first half of 2014, as well as targeting acquisitions that will generate $100 million or more in sales on an annualized basis in 2014 and 2015. The BGS Pharmacy Partners acquisition, for example, will be immediately accretive to PharMerica's bottom line.

Now what: Wall Street may be surprised , but I'm certainly not. The implementation of Obamacare and an expected surge in preventive visits is more than likely going to drive up the need by hospitals and clinics to order medication, providing an instant boost to PharMerica's business. On the flip side, uncertainties surrounding Obamacare have practically all health care companies tightening their belts a bit, and PharMerica's cost-reduction initiatives should handily boost EPS. PharMerica projections for flat year-over-year revenue growth aren't much to look at now, but take into account that it's also topped Wall Street's EPS estimates by double-digits in percentage terms in four straight quarters. I believe this is a name I'd suggest you add to your watchlist and keep an eye on with regard to future top-line growth.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

PharMerica Corporation Stock Quote
PharMerica Corporation

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/04/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.